GlassScriptPhysician profile
Jennifer Barton
NPI 1578967071
$1,694.77
in general payments reported to CMS, 2019-2025
23 companies · $832 in 2025
The $832 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.09 · 2023: $305 · 2024: $534 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $268.88 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $147.83 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $146.70 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $146.37 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $123.95 | 2022-2023 | |
| Pfizer INC. | $122.72 | 2023-2025 | |
| Exact Sciences Corporation | $92.32 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $87.15 | 2024-2025 | Injectafer |
| Lilly USA, LLC | $83.21 | 2024-2025 | Zepbound, Mounjaro |
| Collegium Pharmaceutical, INC. | $71.73 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $57.87 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $51.72 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $45.27 | 2024-2025 | Rexulti |
| Insulet Corporation | $45.07 | 2025 | Omnipod |
| Lundbeck LLC | $34.67 | 2024-2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.81 | 2024-2025 | Repatha, Otezla, Repatha |
| Edwards Lifesciences Corporation | $24.91 | 2025 | |
| Dexcom, INC. | $24.42 | 2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $23.82 | 2025 | Yupelri |
| Gilead Sciences, INC. | $21.84 | 2024 | |
| Mylan Specialty L.P. | $16.07 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2024 | Synjardy, Jardiance |
| Abbvie INC. | $14.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.